Receive our newsletter – data, insights and analysis delivered to you
July 16, 2009

Novartis Positive Despite 12% Decline in First Half

Novartis has remained positive that the company's pharmaceutical business will continue to deliver despite a reported a 12% decrease in net income for the first half of 2009, lowering overall income by $4bn. The decline has largely been blamed on financing costs incurred during the 25% s

By cms admin

Novartis has remained positive that the company’s pharmaceutical business will continue to deliver despite a reported a 12% decrease in net income for the first half of 2009, lowering overall income by $4bn.

The decline has largely been blamed on financing costs incurred during the 25% stake takeover in Alcon, which was acquired in mid-2008.

The company reported a decrease in net income by 10% in the second quarter of 2009 to $2bn, mainly attributed to currency changes and higher financing costs, which included a €1.5bn bond issued in the second quarter of 2009.

Novartis chairman and CEO Dr Daniel Vasella said that he was pleased that the pharmaceuticals business continues to deliver double-digit underlying growth, driven by the strong momentum of recently launched products.

“In the first six months of 2009 we have introduced our new anti-cancer therapy Afinitor in the US and gained first approval for llaris as a new biologic therapy for auto-inflammatory diseases. We are also advancing well in our efforts to rapidly produce and commercialise a vaccine against the H1N1 virus, with clinical trials set to begin in July,” Vasella said

In the first half of 2009 Novartis’ group net sales increased by 8% in local currencies, but declined 2% in US dollars to $20.3bn.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The company’s net sales rose by 8% in local currencies, but fell 2% to $10.5bn from the loss of 10 percentage points of growth to currency movements, during the second quarter of 2009.

Operating income of the company decreased by 4% in the second quarter to $2.4bn, but rose by 13% when adjusted for the impact of adverse currency movements, exceptional items and the amortisation of intangible assets in both periods.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU